Overview
Alejandro Filardi-Montoya practices practicing medicine in Valencia, Spain.
His clinical expertise encompasses Wallerian Degeneration and Corpus Callosum Agenesis.
He is actively involved in clinical research, co-authoring 10 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Alejandro Filardi-Montoya
Is Alejandro Filardi-Montoya a top-rated expert for Wallerian Degeneration?
MediFind is an objective health platform that identifies experts based on real-world data. Alejandro Filardi-Montoya is classified as an Experienced expert for Wallerian Degeneration, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Alejandro Filardi-Montoya participate in research or clinical trials?
Yes. Alejandro Filardi-Montoya has published 10 articles and abstracts on conditions like Wallerian Degeneration. You can view a list of Alejandro Filardi-Montoya's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Corpus Callosum AgenesisMr. Filardi-Montoya isExperienced. Learn about Corpus Callosum Agenesis.
- Wallerian DegenerationMr. Filardi-Montoya isExperienced. Learn about Wallerian Degeneration.